GKOS - Company ID 0001192448
GLAUKOS Corp trades as GKOS and has a market capitalization of $8.97 B, making it the #1025 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $507.44M, up 32.3% from the prior year and net income of -$187.69M. This page tracks GLAUKOS Corp through 1,014 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-12
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years GLAUKOS Corp's revenue grew from $114.40M to $507.44M, a compound annual growth rate of 18.0%. Net profit margin compressed from 4.0% to -37.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider trade | 4 | 2026-05-13 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-04 |
| Insider trade | 4 | 2026-05-04 |
| Insider trade | 4 | 2026-05-04 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:
Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis.
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company’s website here.
_New J-code for Epioxa_ _™_ _, J2789, set to become effective July 1, 2026_
_Conference Call and Webcast Scheduled for 1:30 p.m. PT_
The largest companies sharing GLAUKOS Corp's SEC industry classification (surgical & medical instruments & apparatus).
GLAUKOS Corp (GKOS) has a market capitalization of $8.97 B as of 2026-07-12, ranking #1025 among US-listed companies.
GLAUKOS Corp reported revenue of $507.44M for fiscal year 2025, an increase of 32.3% year over year.
In its latest fiscal year GLAUKOS Corp reported a net loss of $187.69M.